HISUN(SH:600267) Ge Long Hui A P P·2025-11-28 07:58Core Viewpoint - Haizheng Pharmaceutical's product Favipiravir (Hai Fukan) is indicated for the treatment of adult influenza, particularly when other antiviral treatments are ineffective or inadequate, and it has been included in the medical insurance drug list [1] Group 1: Product Information - Favipiravir is a broad-spectrum antiviral drug with RNA polymerase inhibitory properties, showing significant potential against various RNA viruses due to its broad-spectrum antiviral activity and low resistance [1] - The company is actively promoting the accessibility and awareness of Favipiravir by integrating internal and external resources [1] Group 2: Sales and Distribution - Offline sales efforts, including hospital access, are being comprehensively promoted, and patients can also purchase the product through e-commerce channels [1]